A survey on adherence to secondary ischemic stroke prevention

Neurological Research

Volumn 28, Issue 1, 2006, Pages 16-20

  Wang, Yongjun ^a   Wu, Di ^a   Wang, Yilong ^a   Ma, Ruihua ^a   Wang, Chunxue ^a   Zhao, Weijiang ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Antithrombotic therapy; Ischemic stroke; Medical treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; TICLOPIDINE; WARFARIN;

ADULT; AGED; BARTHEL INDEX; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; FOLLOW UP; HEALTH BEHAVIOR; HEALTH INSURANCE; HEALTH SURVEY; HOSPITAL DISCHARGE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; REVIEW; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; TRANSIENT ISCHEMIC ATTACK;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 32144457535     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X91816     Document Type: Review

References (16)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
2. Johnson ES, Lanes SF, Wentwork CE III, et al. A meta regression analysis of the dose-response effect of ASA on stroke. Arch Intern Med 1999; 159: 1248-1253
3. The European Atrial Fibrillation Study Group. Optimal oral anticoagulation therapy with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10
4. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231-1266
5. Adjusted-dose warfarin versus low intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638
6. Landi F, Cesari M, Onder G, et al. Antithrombotic drugs in Secondary stroke prevention among a community dwelling older population. JNNP 2003; 74: 1100-1104
7. Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients follow prescriptions for medications. Cochrane Database Syst Rev 2000; (2): CD000011.
8. Holloway RG, Benesch C, Rush S. Stroke prevention: Narrowing the evidence-practice gap. Neurology 2000; 54: 1899-1906
9. Rudd AG, Lowe D, Hoffman A, et al. Secondary prevention for stroke in the United Kingdom: Results from the National Sentinel Audit of Stroke. Age and Ageing 2004; 33: 280-286
10. Sappok T, Faulstich A, Stuckert E, et al. Compliance with secondary prevention of ischemic stroke: A prospective evaluation. Stroke 2001; 32: 1884-1889
11. Hamann GF, Weimar C, Glahn J, et al. Adherence to secondary stroke prevention strategies - results from the German Stroke Date Bank. Cerebrovasc Dis 2003; 15: 282-288
12. Gencheva E, Sloan M, Leurgans S, et al. Attrition and non-compliance in secondary stroke prevention trials. Neuroepidemiology 2004; 23 (1-2): 61-66
13. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164 (4): 208-211.
14. Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999; 30: 1991-1994
15. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337
16. Hillen T, Dundas R, Lawrence E, et al. Antithrombotic and antihypertensive management 3 months after ischemic stroke. Stroke 2000; 31: 469-475